Technology | February 26, 2007

Chronic HBV Treatment Contains Active Substance New to U.S.

Tyzeka (telbivudine) has just been FDA cleared to treat adults with chronic hepatitis B (HBV), a viral infection that attacks the liver and can cause lifelong infection, scarring of the liver and eventually liver cancer, liver failure and death. Tyzeka is a new molecular entity, which is a term used by the FDA to dexcribe a medication containing an active substance that has never before been approved for marketing in any form in the U.S.

Tyzeka was studied in a year-long international clinical trial in 1,367 patients with chronic HBV. Three-quarters of the trial participants were male, and all were 16 years of age or older. The trail produced evidence of anitviral effectiveness, including the suppression of hepatitis B virus and improvement in liver inflammation comparable to Epivir-HBV (lamivudine), one of five other medications approved to treat patients with chronic HBV.

In clinical studies Tyzeka was generally well tolerated, and most reported adverse events were mild to moderate. The most common side effects were elevated CPK (creatinine phosphokinase, an enzyme that is present in muscle tissue and is a marker for breakdown of muscle tissue), upper respiratory tract infection, fatigue, headache, abdominal pain and cough.

Related Content

Information technology Patient monitoring ecg EMR Philips accenture google glass
News | October 07, 2013
Royal Philips and Accenture announced the creation of a proof-of-concept (POC) demonstration that uses a Google Glass...
News | August 17, 2009
August 17, 2009 - SonoSite Inc., a specialist in hand-carried ultrasound for the point-of-care, announced that on Aug....
News | July 10, 2008
July 11, 2008 - A new study that found wireless systems that track hospital medical equipment can cause potentially...
News | June 24, 2008
June 25, 2008 - Hill-Rom this week said it entered into two new agreements to will enhance and add integrated functio
News | June 17, 2008
June 18, 2008 - Georgetown University, Gentag Inc. and Science Applications International Corp.
News | June 16, 2008
June 17, 2008 - One of the biggest challenges in fighting tuberculosis is simply getting patients to take their medic
Technology | June 15, 2008
The Infinity Omega solution integrates a two-screen patient monitoring solution and consists of a full-function patie
Technology | June 12, 2008
Quest International Inc.
News | June 01, 2008
June 2, 2008 - Cantimer Inc. said today it was awarded a $996,000 contract by the U.S.
News | May 29, 2008
May 30, 2008 – Draeger Service, the Service arm of Draeger Medical Inc., this week launched its Draeger Medical Servi